Meeting
2021 ASCO Annual Meeting
Safety, pharmacokinetics, efficacy, and preliminary biomarker data of first-in-class BI 765063, a selective SIRPα inhibitor: Results of monotherapy dose escalation in phase 1 study in patients with advanced solid tumors.
Authors
Stéphane Champiat
Gustave Roussy Cancer Campus, Department of Drug Development (DITEP), Villejuif, France
Stéphane Champiat , Philippe A. Cassier , Nuria Kotecki , Iphigenie Korakis , Armelle Vinceneux , Christiane Jungels , Jon Blatchford , Mabrouk M. Elgadi , Nicole Clarke , Claudia Fromond , Nicolas Poirier , Berangere Vasseur , Aurelien Marabelle , Jean-Pierre Delord
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Developmental Therapeutics—Immunotherapy
Track
Developmental Therapeutics—Immunotherapy
Sub Track
Other Checkpoint Inhibitors (Non-PD1/PDL1, Monotherapy, or Combination)
Clinical Trial Registration Number
NCT03990233
Citation
J Clin Oncol 39, 2021 (suppl 15; abstr 2623)
DOI
10.1200/JCO.2021.39.15_suppl.2623
Abstract #
2623
Poster Bd #
Online Only
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Annual Meeting
A phase 1 dose-escalation study to investigate the safety, efficacy, pharmacokinetics, and pharmacodynamic activity of cln-619 (Anti-MICA/B antibody) alone and in combination with pembrolizumab in patients with advanced solid tumors.
First Author: Judy S. Wang
Poster
2015 ASCO Annual Meeting
Pharmacokinetic profile and receptor occupancy of avelumab (MSB0010718C), an anti-PD-L1 monoclonal antibody, in a phase I, open-label, dose escalation trial in patients with advanced solid tumors.
First Author: Christopher Ryan Heery
Poster
2023 ASCO Annual Meeting
Sudocetaxel zendusortide (TH1902), a novel sortilin-receptor (SORT1)-targeting peptide-drug-conjugate (PDC) in patients (pts) with advanced solid tumors: Results from part 1 (dose-escalation) of a phase 1, open-label study.
First Author: Funda Meric-Bernstam
Poster
2023 ASCO Annual Meeting
Debio 0123-101: A phase 1 trial of Debio 0123 in combination with carboplatin in advanced solid tumors—Safety, pharmacokinetic, and preliminary antitumor activity data.
First Author: Hans Gelderblom